Injection site reactions after subcutaneous oligonucleotide therapy

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent

(2015) Robert G. Gish et al.   ANTIVIRAL RESEARCH

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Postinflammatory Hyperpigmentation

(2015) Susan Taylor et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys

(2015) Sebastien A. Burel et al.   Nucleic Acid Therapeutics

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces LDL-C in HoFH Pediatric Patients†

(2014) Sheryl Selvey et al.   Journal of Clinical Lipidology

First proof of pharmacology in humans of a novel glucagon receptor antisense drug

(2014) Marloes G. J. van Dongen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

(2014) Thomas Voit et al.   LANCET NEUROLOGY

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

(2014) V. Limmroth et al.   NEUROLOGY

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

(2014) JoAnn D. Flaim et al.   Journal of the American Heart Association

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy

(2014) Maaike van Putten et al.   Molecular Therapy-Nucleic Acids

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

(2013) Mark J. Graham et al.   CIRCULATION RESEARCH

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

(2013) Raul D. Santos et al.   EUROPEAN HEART JOURNAL

Long Term Efficacy and Safety of Mipomersen During 4 Years of Treatment in a Cohort of Patients with Heterozygous Familial Hypercholesterolemia and Coronary Artery Disease (CAD)

(2013) P. Bart Duell et al.   Journal of Clinical Lipidology

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial

(2013) Kevin M. Flanigan et al.   NEUROMUSCULAR DISORDERS

Treatment of HCV Infection by Targeting MicroRNA

(2013) Harry L.A. Janssen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

(2012) B. Yu et al.   BLOOD

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

(2012) Evan A. Stein et al.   CIRCULATION

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk†

(2012) William C. Cromwell et al.   Journal of Clinical Lipidology

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION

(2012) H.W. Reesink et al.   JOURNAL OF HEPATOLOGY

EFFECT OF MIPOMERSEN ON LIPOPROTEIN(A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA ACROSS FOUR PHASE III STUDIES

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals

(2012) Punit P Seth et al.   Molecular Therapy-Nucleic Acids

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists

(2011) Ekambar R. Kandimalla et al.   CELLULAR IMMUNOLOGY

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia †

(2011) Jean-Claude Tardif et al.   Journal of Clinical Lipidology

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

(2011) Clive S. Zent et al.   LEUKEMIA & LYMPHOMA

Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy

(2011) Nathalie M. Goemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications

(2010) Rakesh N. Veedu et al.   CHEMISTRY & BIODIVERSITY

Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers

(2010) H. DAUCHEL et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Drug-elicited systemic allergic (contact) dermatitis - update and possible pathomechanisms

(2010) Jacob Pontoppidan Thyssen et al.   CONTACT DERMATITIS

Mipomersen as a potential adjunctive therapy for hypercholesterolemia

(2010) Neeraj Patel et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mipomersen, a First-in-Class Apolipoprotein B Synthesis Inhibitor, Lowers Lipoprotein (a) in Patients with Homozygous Familial Hypercholesterolemia

(2010) William C. Cromwell et al.   Journal of Clinical Lipidology

Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-α and enhance Th1-mediated immunity

(2010) Sun-Shim Choi et al.   JOURNAL OF MICROBIOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Crosstalk pathways between Toll-like receptors and the complement system

(2010) George Hajishengallis et al.   TRENDS IN IMMUNOLOGY

Functional Comparison of Innate Immune Signaling Pathways in Primates

(2010) Luis B. Barreiro et al.   PLoS Genetics

Stimulation of the Immune System by Therapeutic Antisense Oligodeoxynucleotides and Small Interfering RNAs via Nucleic Acid Receptors

(2009) Denise Richardt-Pargmann et al.   Annals of the New York Academy of Sciences

CpG-ODNs induces up-regulated expression of chemokine CCL9 in mouse macrophages and microglia

(2009) C. Ravindran et al.   CELLULAR IMMUNOLOGY

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

(2009) John A. Thompson et al.   Clinical Genitourinary Cancer

Drug-induced cutaneous pathology

(2009) P K Ramdial et al.   JOURNAL OF CLINICAL PATHOLOGY

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

(2009) Maartje E. Visser et al.   JOURNAL OF LIPID RESEARCH

Predictivity of animal studies for human injection site reactions with parenteral drug products

(2008) Jeffery A. Engelhardt   EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY

The DNA Sugar Backbone 2′ Deoxyribose Determines Toll-like Receptor 9 Activation

(2008) Tobias Haas et al.   IMMUNITY